NO308107B1 - Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel - Google Patents

Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel

Info

Publication number
NO308107B1
NO308107B1 NO953657A NO953657A NO308107B1 NO 308107 B1 NO308107 B1 NO 308107B1 NO 953657 A NO953657 A NO 953657A NO 953657 A NO953657 A NO 953657A NO 308107 B1 NO308107 B1 NO 308107B1
Authority
NO
Norway
Prior art keywords
compound
preparation
formulation containing
pharmaceutical
unsolvated crystalline
Prior art date
Application number
NO953657A
Other languages
English (en)
Norwegian (no)
Other versions
NO953657D0 (no
NO953657L (no
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
Iii John Mcneill Mcgill
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308107(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO953657D0 publication Critical patent/NO953657D0/no
Publication of NO953657L publication Critical patent/NO953657L/no
Publication of NO308107B1 publication Critical patent/NO308107B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO953657A 1994-09-19 1995-09-15 Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel NO308107B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (3)

Publication Number Publication Date
NO953657D0 NO953657D0 (no) 1995-09-15
NO953657L NO953657L (no) 1996-03-20
NO308107B1 true NO308107B1 (no) 2000-07-24

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
NO953657A NO308107B1 (no) 1994-09-19 1995-09-15 Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel
NO19953658A NO313996B1 (no) 1994-09-19 1995-09-15 Krystallinsk solvat av forbindelsen 6-hydroksy-2-(4- hydroksyfenyl)-3-[4-(2-piperidinoetoksy)benzoyl]benzo[b]tiofenhydroklorid, fremgangsmåtefor fremstilling av solvatet, og fremgangsmåte for fremstilling av en ikke-solvatisert utgaveav forbind

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19953658A NO313996B1 (no) 1994-09-19 1995-09-15 Krystallinsk solvat av forbindelsen 6-hydroksy-2-(4- hydroksyfenyl)-3-[4-(2-piperidinoetoksy)benzoyl]benzo[b]tiofenhydroklorid, fremgangsmåtefor fremstilling av solvatet, og fremgangsmåte for fremstilling av en ikke-solvatisert utgaveav forbind

Country Status (51)

Country Link
US (4) US6399778B1 (cs)
JP (2) JPH08193081A (cs)
KR (2) KR100367376B1 (cs)
CN (2) CN1068324C (cs)
AP (1) AP754A (cs)
AT (2) AT502957A1 (cs)
AU (3) AU692907B2 (cs)
BE (2) BE1009626A3 (cs)
BG (1) BG62793B1 (cs)
BR (2) BR9504060A (cs)
CA (2) CA2158399C (cs)
CH (3) CH691125A5 (cs)
CO (2) CO4410190A1 (cs)
CZ (2) CZ292007B6 (cs)
DE (3) DE19534745B4 (cs)
DK (4) DK175897B1 (cs)
EE (1) EE03386B1 (cs)
EG (1) EG23763A (cs)
ES (2) ES2109882B1 (cs)
FI (2) FI112226B (cs)
FR (2) FR2724655B1 (cs)
GB (2) GB2293382B (cs)
GE (1) GEP19991821B (cs)
GR (2) GR1002697B (cs)
HK (1) HK1019009A1 (cs)
HR (2) HRP950483B1 (cs)
HU (2) HU225417B1 (cs)
IE (2) IE950722A1 (cs)
IL (3) IL115314A (cs)
IS (1) IS1788B (cs)
IT (2) IT1277601B1 (cs)
LU (2) LU88661A1 (cs)
LV (2) LV11178B (cs)
MY (1) MY116371A (cs)
NL (2) NL1001194C2 (cs)
NO (2) NO308107B1 (cs)
NZ (2) NZ280028A (cs)
OA (1) OA10406A (cs)
PE (2) PE14796A1 (cs)
PL (2) PL187686B1 (cs)
PT (2) PT101770B (cs)
RO (2) RO115260B1 (cs)
RS (2) RS49513B (cs)
SE (2) SE509265C2 (cs)
SI (2) SI9500293A (cs)
SK (1) SK283502B6 (cs)
TR (1) TR199501136A2 (cs)
TW (1) TW412534B (cs)
UA (2) UA42716C2 (cs)
UY (1) UY24040A1 (cs)
WO (1) WO1996009045A1 (cs)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA992858B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
US6921827B2 (en) * 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1546138B1 (en) * 2002-09-30 2012-01-18 A/S GEA Farmaceutisk Fabrik Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
KR101239489B1 (ko) 2004-09-29 2013-03-06 바이엘 파마 악티엔게젤샤프트 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN103951667A (zh) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8344149B2 (en) * 2006-10-17 2013-01-01 Cipla Limited Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (en) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
WO2009150669A1 (en) * 2008-06-09 2009-12-17 Erregierre S.P.A. Process for controlling the growth of a raloxifene hydrochloride crystal
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
EA033415B1 (ru) 2010-05-05 2019-10-31 Boehringer Ingelheim Int Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
NZ618698A (en) 2011-07-15 2015-08-28 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4358593A (en) 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
IL65378A (en) 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
IL65379A0 (en) 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
PH18628A (en) * 1981-04-03 1985-08-23 Lilly Co Eli "6-hydroxy-2-(4-hydroxyphenyl)-3 4-(2- piperidine or 3-methylpyrollidine -benzo b thiophene compounds
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69405491T2 (de) * 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
DE19534745B4 (de) 2004-06-09
HRP950482A2 (en) 1998-02-28
HU9502721D0 (en) 1995-11-28
ITMI951935A0 (it) 1995-09-15
IL125283A (en) 2001-06-14
NO953658L (no) 1996-03-20
ES2129293B1 (es) 2000-01-16
NZ280027A (en) 1997-05-26
SK23397A3 (en) 1997-08-06
NZ280028A (en) 1997-05-26
PT101771A (pt) 1996-04-30
US6399778B1 (en) 2002-06-04
PE32796A1 (es) 1996-08-07
PL310517A1 (en) 1996-04-01
YU61395A (sh) 1998-09-18
HU225417B1 (en) 2006-11-28
SK283502B6 (sk) 2003-08-05
JPH08176147A (ja) 1996-07-09
CZ290343B6 (cs) 2002-07-17
DE19534745A1 (de) 1996-04-04
ES2109882B1 (es) 1998-08-16
FI121424B (fi) 2010-11-15
KR100381346B1 (ko) 2004-04-13
EG23763A (en) 2007-08-08
HU227683B1 (en) 2011-11-28
IS4446A (is) 1997-03-18
DK175897B1 (da) 2005-05-30
JPH08193081A (ja) 1996-07-30
SE9503213L (sv) 1996-03-20
DK175886B1 (da) 2005-05-23
HRP950483B1 (en) 2003-02-28
ITMI951936A1 (it) 1997-03-15
LU88660A1 (fr) 1996-07-15
SI9500292A (en) 1996-06-30
PL182450B1 (pl) 2002-01-31
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
FR2724655A1 (fr) 1996-03-22
RS49513B (sr) 2006-10-27
RO115259B1 (ro) 1999-12-30
GB9519032D0 (en) 1995-11-15
GEP19991821B (en) 1999-11-05
FI954402A (fi) 1996-03-20
SE9503214D0 (sv) 1995-09-15
UA42716C2 (uk) 2001-11-15
CH691478A5 (de) 2001-07-31
SE9503214L (sv) 1996-03-20
FI954403A (fi) 1996-03-20
CZ240295A3 (en) 1996-04-17
HU9502723D0 (en) 1995-11-28
ES2129293A1 (es) 1999-06-01
KR960010637A (ko) 1996-04-20
NO953657D0 (no) 1995-09-15
PE14796A1 (es) 1996-05-19
LV11177A (lv) 1996-04-20
TW412534B (en) 2000-11-21
AP754A (en) 1999-07-22
CH691125A5 (de) 2001-04-30
BR9504059A (pt) 1996-09-24
ITMI951935A1 (it) 1997-03-15
AP9700938A0 (en) 1997-04-30
US5731327A (en) 1998-03-24
ES2109882A1 (es) 1998-01-16
NL1001194C2 (nl) 1997-04-04
EE9700055A (et) 1997-08-15
DK175887B1 (da) 2005-05-23
NL1001196C2 (nl) 1997-04-04
CN1075069C (zh) 2001-11-21
CZ292007B6 (cs) 2003-07-16
BE1009625A3 (fr) 1997-06-03
PT101771B (pt) 1997-04-30
US20020173645A1 (en) 2002-11-21
OA10406A (en) 2001-12-05
FI954403A0 (fi) 1995-09-18
AU3173195A (en) 1996-04-04
PT101770B (pt) 1997-04-30
DE19549755B4 (de) 2005-05-04
DK102895A (da) 1996-03-20
RS49578B (sr) 2007-04-10
FR2732020B1 (fr) 1997-11-14
TR199501136A2 (tr) 1996-06-21
PT101770A (pt) 1996-04-30
CN1132205A (zh) 1996-10-02
AU692907B2 (en) 1998-06-18
HUT75033A (en) 1997-03-28
CO4410190A1 (es) 1997-01-09
DK2897A (da) 1997-01-09
ATA154295A (de) 2000-12-15
CH691594A5 (de) 2001-08-31
NO313996B1 (no) 2003-01-13
IE80883B1 (en) 1999-05-19
NO953657L (no) 1996-03-20
US6472531B1 (en) 2002-10-29
IL115315A (en) 1999-09-22
UA44240C2 (uk) 2002-02-15
IE950722A1 (en) 1996-03-20
LV11178A (lv) 1996-04-20
HRP950482B1 (en) 2007-04-30
AU691955B2 (en) 1998-05-28
AT407988B (de) 2001-07-25
WO1996009045A1 (en) 1996-03-28
RO115260B1 (ro) 1999-12-30
DK175903B1 (da) 2005-06-06
CN1068324C (zh) 2001-07-11
GB2293602A (en) 1996-04-03
HUT74178A (en) 1996-11-28
LV11178B (en) 1996-08-20
CO4410191A1 (es) 1997-01-09
GB9519028D0 (en) 1995-11-15
LV11177B (en) 1996-08-20
DK102795A (da) 1996-03-20
AU3173095A (en) 1996-04-04
IE950721A1 (en) 1996-03-20
JP2860071B2 (ja) 1999-02-24
BG62793B1 (bg) 2000-08-31
CN1127253A (zh) 1996-07-24
MY116371A (en) 2004-01-31
DK2797A (da) 1997-01-09
FI954402A0 (fi) 1995-09-18
HK1019009A1 (en) 2000-01-14
KR100367376B1 (ko) 2003-03-06
AT502957A1 (de) 2007-06-15
NL1001196A1 (nl) 1996-03-19
NO953658D0 (no) 1995-09-15
CZ240395A3 (en) 1996-04-17
IL115314A (en) 2000-02-29
SE520721C2 (sv) 2003-08-12
SI9500293A (en) 1996-06-30
GR1002709B (el) 1997-06-04
BG101242A (en) 1998-03-31
EE03386B1 (et) 2001-04-16
SE509265C2 (sv) 1998-12-21
CA2158400C (en) 2006-10-24
GB2293602B (en) 1998-05-06
NL1001194A1 (nl) 1996-03-19
BR9504060A (pt) 1996-09-24
PL187686B1 (pl) 2004-09-30
LU88661A1 (fr) 1996-07-15
FR2724655B1 (fr) 1997-11-14
IL115315A0 (en) 1995-12-31
YU61495A (sh) 1998-05-15
CA2158400A1 (en) 1996-03-20
FI112226B (fi) 2003-11-14
GR1002697B (el) 1997-05-22
IL115314A0 (en) 1996-05-14
HRP950483A2 (en) 1997-10-31
BE1009626A3 (fr) 1997-06-03
UY24040A1 (es) 1996-03-07
PL310518A1 (en) 1996-04-01
ITMI951936A0 (it) 1995-09-15
IS1788B (is) 2001-11-28
FR2732020A1 (fr) 1996-09-27
IT1277601B1 (it) 1997-11-11
GB2293382B (en) 1998-08-19
DE19534744A1 (de) 1996-03-21
CA2158399A1 (en) 1996-03-20
KR960010634A (ko) 1996-04-20
SE9503213D0 (sv) 1995-09-15
IT1277602B1 (it) 1997-11-11
GB2293382A (en) 1996-03-27

Similar Documents

Publication Publication Date Title
NO308107B1 (no) Ikke-solvatert krystallinsk forbindelse, farmasøytisk formulering inneholdende denne samt anvendelse av forbindelsen for fremstilling av et farmasøytisk middel
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
NO304488B1 (no) 5-leddede heteroaryloksazolidinoner, anvendelse av disse for fremstilling av legemidler samt legemiddel inneholdende forbindelsen
NO306725B1 (no) Ny krystallmodifikasjon av CDCH, fremgangsmate for fremstilling derav og farmasoytiske preparater inneholdende denne samt anvendelse av forbindelsen for fremstilling av legemidler
HUP9902092A3 (en) Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
IL135176A0 (en) Benzothiazole derivatives and pharmaceutical compositions containing the same
NO942864L (no) Benzokondenserte 5-ringheterocykler, fremgangsmåte for fremstilling derav, deres anvendelse som medikament, deres anvendelse som diagnostikum samt medikament inneholdene disse
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
AU2109195A (en) Two-component device for the administration of drugs
NO944526D0 (no) Medisinsk aerosolformulering
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
NO20040145L (no) Anvendelse av benzensulfonamidderivater for fremstilling av et medikament
DE69528769D1 (de) Aerosolformulierung für arzneimittel enthaltend polyglycolisierte glyzeride
NO964639L (no) Substituerte sulfonimidamider, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
IL133097A0 (en) Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
NO305906B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
BR9610821A (pt) Derivado de aminoácido uso de um composto e medicamento contendo o mesmo
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
NO306347B1 (no) Eleutherobin og analoger av denne, anvendelse av forbindelsen samt farmasöytisk preparat inneholdende denne
HUP0100853A3 (en) Nitrate salt of anti-ulcer medicine and pharmaceutical compositions containing the same compounds
NO308527B1 (no) Substituerte 2-naftoylguanidiner, deres anvendelse for fremstilling av et medikament samt legemidler og preparater inneholdende forbindelsene
NO306113B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
HUP9901873A3 (en) Benzisoxazole and benzisoxazolidinone derivatives, preparation of the latter, herbicide compositions containing these compounds and use thereof
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
NO308251B1 (no) Karbohydratderivater, farmasøytisk blanding inneholdende karbohydratderivater samt anvendelse av samme

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees